Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -164.0%. (2015–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $697790 | $2M | $17M | $26M | $21M | $14M | $12M | $29.9B | $302.7B | $430.7B | $1.4B |
| Enterprise Value | $-1514872 | $-433345 | $11M | $14M | $-8610306 | $4M | $9M | $29.9B | $302.7B | $430.7B | $1.3B |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 2.72 | 3.58 | 35646.01 | 237508.17 | 426175.78 | — |
| P/B Ratio | 0.03 | 1.18 | 3.23 | 2.52 | 0.53 | 0.64 | 1.17 | 3218.49 | 10400.09 | 7261.28 | 15.24 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 0.69 | 2.65 | 35634.28 | 237493.12 | 426153.60 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | 100.0% | 48.6% | 60.3% | 34.4% | — |
| Operating Margin | — | — | — | — | — | -148.8% | -238.5% | -2633.7% | -2724.6% | -3946.5% | — |
| Net Profit Margin | — | — | — | — | — | -140.5% | -200.2% | -2615.6% | -2701.7% | -3907.6% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.0% | -164.0% | -160.1% | -128.7% | -41.9% | -44.9% | -69.8% | -114.2% | -77.9% | -52.1% | -31.6% |
| ROA | -116.0% | -116.0% | -118.1% | -113.9% | -38.8% | -37.9% | -57.1% | -96.6% | -70.1% | -49.9% | -30.7% |
| ROIC | — | — | — | -613.4% | -91.4% | -61.9% | -182.4% | -353.3% | -111.2% | -95.9% | -85.9% |
| ROCE | -168.7% | -168.7% | -164.6% | -129.7% | -42.1% | -47.6% | -103.6% | -127.9% | -78.5% | -52.6% | -31.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.05 | — | — | 0.02 | 0.05 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.46 | -1.06 | -1.17 | -0.75 | -0.48 | -0.31 | -1.06 | -0.66 | -0.38 | -0.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -2555.41 | — | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($221866)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.06 | 5.91 | 16.06 | 32.40 |
| Quick Ratio | 1.98 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.02 | 5.83 | 15.94 | 32.40 |
| Cash Ratio | 1.61 | 1.61 | 4.54 | 2.84 | 13.84 | 4.01 | 1.13 | 1.96 | 5.70 | 15.70 | 32.08 |
| Asset Turnover | — | — | — | — | — | 0.21 | 0.25 | 0.08 | 0.04 | 0.02 | — |
| Inventory Turnover | 2.30 | — | — | — | — | — | — | 2.30 | 1.17 | 1.46 | — |
| Days Sales Outstanding | — | — | — | — | — | 268.94 | — | 4.33 | 2.97 | 4.40 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 1.1% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $64468 | $218730 | $142342 | $13858 | $5219 | $1095 | $1M | $1M | $1M | $1504 |
Imminent liquidity and dilution
Based on reported figures, the company's price-to-book ratio of 0.03 suggests that the market is heavily discounting the firm's assets, likely due to the high probability of further dilutive financing requirements and the binary nature of upcoming clinical trial readouts for its lead oncology candidates.
The extremely low P/B multiple indicates that investors are assigning minimal value to the company's intellectual property and pipeline, viewing the firm primarily through the lens of its immediate survival risk. This valuation gap compared to peers like Immunovant suggests that the market requires significant clinical validation before re-rating the stock, as current pricing implies a high likelihood of equity impairment.
According to recent SEC filings, the current ratio has fluctuated significantly, reaching 5.49 in 2025Q3, yet this headline figure masks the reality that the company's cash runway is rapidly depleting, leaving little room for operational error or unexpected delays in the clinical trial enrollment process.
While the current ratio appears superficially healthy, it is heavily influenced by the timing of grant-related receivables and the absence of significant short-term liabilities. Investors should monitor the cash burn rate closely, as the current liquidity position may be insufficient to sustain the company's research-heavy cost structure through the next major data inflection point.
As reported in financial statements, the company maintains a minimal debt-to-equity profile, yet this lack of traditional leverage is deceptive, as the firm's reliance on equity-based financing and potential warrant exercises creates a persistent risk of shareholder dilution that is not captured by standard debt metrics.
The absence of significant interest-bearing debt is typical for a clinical-stage biotech, but it does not imply financial stability. The company's reliance on external capital markets to fund its operations means that any volatility in the broader biotech sector could severely restrict its ability to secure the necessary funding to continue as a going concern.
Investors frequently misapply traditional profitability ratios like net margin to Salarius, which obscures the reality that the company is a pre-revenue entity where negative earnings are a structural feature of its R&D-intensive business model rather than a sign of operational failure or mismanagement.
Using net margin or P/E ratios to evaluate this company is fundamentally flawed because these metrics ignore the value of the underlying clinical pipeline. Analysts should instead focus on the 'Cash Runway to Data Readout' and 'Net Cash Used in Operating Activities' to assess the company's ability to reach the next value-creating milestone without exhausting its capital base.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLRX stock.
Salarius Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Salarius Pharmaceuticals, Inc.'s return on equity (ROE) is -164.0%. The historical average is -88.5%.
Based on historical data, Salarius Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.